Alvogen's Lotus Secures Deal With Fuji To Bolster Asia Presence
Alvogen’s Taiwanese subsidiary Lotus has confirmed a cross-investment partnership with Fuji that will strengthen the firms’ commercial platform in Japan and other key Asian pharmaceutical markets.
You may also be interested in...
Lotus Pharmaceuticals has expanded its biosimilar pipeline to five by bringing in rights in Taiwan and South East Asia markets to Chong Kun Dang Pharmaceutical’s biosimilar of Kyowa Kirin’s Nesp (darbepoetin alfa).
Alvogen has struck a deal with Insud’s Exeltis to gain rights to 23 women’s healthcare brands in Russia, Ukraine and Kazakhstan.
Alvotech and Fuji Pharma have extended their alliance to cover exclusive development and supply of biosimilar ustekinumab in Japan.